N-(5-Methylisoxazol-3-yl)butyramide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(5-Methylisoxazol-3-yl)butyramide
• 英文别名: N-(5-methyl-1,2-oxazol-3-yl)butanamide
• 化学式: C₈H₁₂N₂O₂
• mdl: MFCD03377374
• 分子量: 168.19
• InChiKey: LDGOGFXHKZUPIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BIPHENYLMETHANE DERIVATIVE AND MEDICINE CONTAINING THE SAME
  申请人：WAKUNAGA SEIYAKU KABUSHIKI KAISHA

  公开号：EP0656355A1

  公开（公告）日：1995-06-07

  A biphenylmethane derivative represented by general formula (I), a salt thereof, and a remedy for circulatory system diseases containing the same, wherein A represents the group (II) or (III) wherein R¹ represents hydrogen, lower alkyl, lower cycloalkyl, optionally substituted phenyl, optionally substituted aralkyl, optionally substituted acyl, or amino acid residue; X represents oxygen or sulfur; Y represents nitrogen or =CR²-; Z represents oxygen, nitrogen or =CR³- (excluding the case where both of Y and Z represent nitrogen simultaneously); R² and R³ represent each independently hydrogen, halogen, optionally substituted lower alkyl, optionally protected carboxyl, lower cycloalkyl, lower alkenyl, lower alkoxy, lower alkylthio or aryl, or alternatively R², R³ and the adjacent carbon atoms may be combined together to form an optionally substituted benzene ring; and B represents cyano, optionally protected carboxyl or optionally protected tetrazol-5-yl. This compound has such potent angiotensin II antagonism and hypotensive effect that it is useful for treating circulatory system diseases such as hypertension, cardiac diseases and cerebral apoplexy.

  通式(I)代表的联苯甲烷衍生物、其盐和含有该衍生物的治疗循环系统疾病的药物，其中A代表基团(II)或(III)，其中R¹代表氢、低级烷基、低级环烷基、任选取代的苯基、任选取代的芳烷基、任选取代的酰基或氨基酸残基；X代表氧或硫；Y代表氮或＝CR²-；Z 代表氧、氮或 =CR³-（不包括 Y 和 Z 同时代表氮的情况）；R² 和 R³ 各自独立地代表氢、卤素、任选取代的低级烷基、任选保护的羧基、低级环烷基、低级烯基、低级烷氧基、低级烷硫基或芳基，或者 R²、R³ 和相邻碳原子可以结合在一起形成任选取代的苯环；B 代表氰基、任选保护的羧基或任选保护的四唑-5-基。该化合物具有很强的血管紧张素 II 拮抗和降压作用，可用于治疗高血压、心脏病和脑中风等循环系统疾病。
• AGENT FOR IMPROVEMENT IN BOUNCE/BODY OF HAIR, AND HAIR COSMETIC
  申请人：Shiseido Company, Limited

  公开号：EP1911750A1

  公开（公告）日：2008-04-16

  A hair resiliency and body improver comprising as the active ingredient thereof one or more types of compounds selected from the group consisting of 2-aminothiazole derivatives represented by the following general formula (1) or 3-aminoisoxazole derivatives represented by the following general formula (2), and pharmaceutically acceptable salts thereof: (wherein, R1, R2, R3, R4, n and m are as defined in the description).

  一种头发弹性和发质改善剂，其活性成分包括一种或多种选自由下通式 (1) 所代表的 2-氨基噻唑衍生物或自由下通式 (2) 所代表的 3-氨基异恶唑衍生物组成的组的化合物及其药学上可接受的盐类： (其中，R1、R2、R3、R4、n 和 m 如说明中所定义）。
• Hair resiliency / body improver and hair cosmetic
  申请人：Shiseido Company, Limited

  公开号：EP2484342A1

  公开（公告）日：2012-08-08

  A hair resiliency and body improver comprising as the active ingredient thereof one or more types of compounds selected from the group consisting of 2-aminothiazole derivatives represented by the following general formula (1) or 3-aminoisoxazole derivatives represented by the following general formula (2), and pharmaceutically acceptable salts thereof: (wherein, R1, R2, R3, R4, n and m are as defined in the description).

  一种头发弹性和发质改善剂，其活性成分包括一种或多种选自由下通式 (1) 所代表的 2-氨基噻唑衍生物或自由下通式 (2) 所代表的 3-氨基异恶唑衍生物组成的组的化合物及其药学上可接受的盐类： (其中，R1、R2、R3、R4、n 和 m 如说明中所定义）。
• CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS
  申请人：Reed John C.

  公开号：US20090069324A1

  公开（公告）日：2009-03-12

  Compounds that bind to Bfl-1 as well as conjugates of such compounds are provided. Various embodiments additionally provide methods of using such compounds to identify additional anti-apoptotic Bfl-1 binding compounds. Methods of using such compounds to increase apoptosis in a cell are also provided.
• Hair resiliency/body improver and hair cosmetic
  申请人：Suetsugu Masaru

  公开号：US20090233975A1

  公开（公告）日：2009-09-17

  A hair resiliency and body improver comprising as the active ingredient thereof one or more types of compounds selected from the group consisting of 2-aminothiazole derivatives represented by the following general formula (1) or 3-aminoisoxazole derivatives represented by the following general formula (2), and pharmaceutically acceptable salts thereof: (wherein, R 1 , R 2 , R 3 , R 4 , n and m are as defined in the description).